

ISSN 2689-0852

BIOTECHNOLOGY



KIOSK

VOLUME 3, ISSUE 2
FEBRUARY 2021



**NANOMATERIAL SOLUTIONS
TO MITIGATE COVID-19**

www.biotechkiosk.com



Executive Publishers

Megha Agrawal, PhD

(Biotechnology)

Publisher and Editor

Expertise:

Neuroscience, Stroke, Pharmacology,
Toxicology, Microbiology, Antiaging,
Gene Therapy and Immunology

Email: megha@biotechkiosk.com
meghaagra@gmail.com

Shyamasri Biswas, PhD

(Biotechnology)

Publisher and Editor

Expertise:

Structural Biology, Enzyme Technology,
Protein Crystallography, Molecular Biology
and Mass Spectrometry

Email: shyabiswas@biotechkiosk.com
shyabiswas@gmail.com

Cover page artwork is by Harsh Grover

Editorial, Sales & Circulation Office

1330 NW 6th Street
Suite A2, Gainesville
FL-32601, USA

Phone: 386-518-9411



Email: publisher@biotechkiosk.com

www.biotechkiosk.com

ISSN 2689-0852

One stop shop for all things biotech





Biotechnology Kiosk

biotechkiosk.com | ISSN 2689-0852
A Premier Medium of Research Publications
in All Areas of Biotechnology

Special Edition on COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, officially COVID-19) and its subsequent rapid spread across the world has put the global health at risk. The pandemic has taken millions of lives across the globe. Researchers are putting their best efforts to gain insights into the epidemiology along with the discovered genome structure and important viral factors of SARS-CoV-2, and employing biotechnology-based innovative solutions for the development of new rapid diagnostics including point-of-care diagnostics and surveillance technologies. This is aimed at detecting SARS-CoV-2 early in order to control the disease and mitigate it in a timely fashion. These efforts have also focused on investigating therapeutics including significant breakthroughs in clinical trials on antiviral drugs and vaccines to mitigate the challenges of COVID-19. Manuscripts are invited from authors for publication in this special edition that intends to provide the reader with a comprehensive overview of the current state-of-the-art in epidemiology, transmission and genome structure along with the latest breakthroughs in diagnostics, therapeutics and vaccines to combat COVID-19. The following list includes, but not limited to the topics that will be covered in this special edition. Authors can e-mail their manuscripts directly to one of the following editors of this special edition. All manuscripts will be peer-reviewed and will be published free of charge.

- Epidemiology and Transmission
- Genome Structure
- Viral Protein, Crystal Structure, Sequencing
- Diagnostics and Surveillance
- PCR, Point-of-Care, Microfluidics
- Therapeutics
- Anti-viral drugs, Repurposing, Therapeutic Targets
- Vaccines
- m-RNA, Antibody, Protein Engineering, Clinical Studies
- Socio, Scientific and Economic Effects of COVID-19
- Co-morbidity and Neurological Conditions and COVID-19

Last Date for Submission: Aug 15, 2021; Publication Date: Aug 31, 2021

Dr. Megha Agrawal, PhD
Chief Editor of Biotechnology Kiosk
E-mail: meghaagra@gmail.com
megha@biotechkiosk.com

Dr. Shyamasri Biswas, PhD
Chief Editor of Biotechnology Kiosk
E-mail: shyabiswas@gmail.com
shyabiswas@biotechkiosk.com

Dr. Maqsood A. Siddiqui, PhD
Associate Editor of Biotechnology Kiosk
E-mail: maqsoodahmads@gmail.com

Dr. Adonis Sfera, MD
Associate Editor of Biotechnology Kiosk
E-mail: ADONIS.SFERA@dsh.ca.gov



From the Publisher's Desk

Welcome to Biotechnology Kiosk!

The February' 2021 issue of BK is now online for our readers with the regular features. This issue contains a mini-review on cancer therapy and the regular editor's picks on some exciting developments in stem cell transplant in preventing long term disability from multiple sclerosis (MS) and links of gut microbe with breast cancer.

We hope our readers will enjoy reading these news and views on the current cutting-edge topics that include latest

research breakthroughs in different areas of medicine and biotechnology.

We look forward to receiving your feedback. We do hope that you will enjoy reading this issue of Biotechnology Kiosk. Please do write to us with your comments. Your suggestions are always appreciated.

Dr. Megha Agrawal & Dr. Shyamasri Biswas.

Editors-in-Chief, Biotechnology Kiosk






Contents

Volume 3, Issue 2

February 2021

Mini-review.....	5
Advanced Nanomaterial Based Solutions to Mitigate the Challenges Of COVID-19 Pandemic https://doi.org/10.37756/bk.21.3.2.1	
BIOTECH R&D AND INNOVATION NEWS.....	25
Editor's Picks: Biotechnology Advances around the World	
Stem cell transplant in multiple sclerosis.....	26
Gut microbe is linked to the development of breast cancer	27





REDUCING HEALTH COSTS IMPROVING PATIENT OUTCOMES

HELPING PATIENTS HELP THEMSELVES.

Most of the organizations involved in healthcare are trying to improve health outcomes while managing cost.

Research indicates that, we must engage patients, their families and their caregivers to reduce re-hospitalizations, increase medication and treatment plan adherence and manage chronic diseases.



ICmed is a Patient and Family-Centered Solution. Simple, Elegant and Easy.

1 Patient & Family Mobile App

ICmed's solution gives your population (patients, employees and clients), along with their family and caregivers, a powerful mobile app to track, manage and improve their health.

2 Enterprise Dashboard

Your organization would license the solution and manage the dashboard, which is digitally connected to your population through the mobile app.

From the dashboard you can:



Remotely Monitoring Vitals



Send Secured Messaging: Voice & Chat



Conduct Surveys & Assessments



Send Alerts & Notifications



Create Appointments & Schedules



Chronic Care Management

3 Tailored Use Cases

ICmed can customize a solution to meet your needs. Use case scenarios include:



Remote Patient Monitoring



Chronic Disease Management



Pre & Post-natal Care



Employee Wellness



Population Health Management



Vaccination Administration

ICmed consultants tailor each license to align seamlessly with your need and workflow. License agreements span one, two or three years.

www.icmedonline.com

For more information, contact
partner@icmedonline.com

<https://www.icmedonline.com>

Advanced Nanomaterial Based Solutions to Mitigate the Challenges of COVID-19 Pandemic

Ashish Yadav^{1*}, Ashish Mathur², Zheng Hongyu¹, Rajeev Gupta², John Baptist Kirabira³, Kenneth Ssekataawa³

¹Center for Advanced Laser Manufacturing (CALM), Shandong University of Technology, Zibo, 255000, China

²Department of Physics, School of Engineering, University of Petroleum & Energy Studies, Dehradun-248007, Uttarakhand, India

³Africa Center of Excellence in Materials, Product Development and Nano-Technology (MAPRONANO-ACE), Department of Mechanical Engineering, College of Engineering Design, Art and Technology, Makerere University, P.O. BOX 7062, Kampala, Uganda



DOI: <https://doi.org/10.37756/bk.21.3.2.1>

Article type: *Mini-review*

Received: *January, 2021*

Revised: *January 15, 2021*

Accepted: *January 17, 2021*

To cite this article: Yadav A et.al., Advanced Nanomaterial Based Solutions To Mitigate The Challenges Of COVID-19 Pandemic, Biotechnol. kiosk, Vol 3, Issue 2, PP: 5-24 (2021); DOI: <https://doi.org/10.37756/bk.21.3.2.1>.

Abstract

The worldwide healthcare response to combat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, COVID-19) has led to the developments of several highly specialized techniques for diagnosis, for example, whole genome sequencing and computed tomography imaging. Considerable effort is also being directed towards detecting and preventing different modes of community transmission. One such mode of transmission, the presence of the virus on various surfaces that people may come in contact with, is being countered with the rapid detection. To this end, non-contact, optical techniques-based detection of COVID-19 have been shown to be useful for early prevention of spread of the virus by identifying infected surfaces. Especially, researchers have demonstrated nanomaterials-enabled diagnostic methods for rapid and early detection of SARS-CoV-2. It is believed that nanotechnology-based innovations particularly in the fields of diagnostics and therapeutics can provide solutions to the very complex problems of COVID-19 pandemic. Here, we present a critical overview of recent literature that specifically addresses how nano-engineered materials are enabling the effective and rapid diagnosis of COVID-19. Prominent techniques are described that show high accuracy of detection even in trace concentrations, which is achieved by measuring color change and also light-sensitive nanomaterials. Fingerprint techniques that enable identification of virus that is present at the surface are also described. Finally, we present a brief perspective of using nanomaterials in diagnostics, monitoring and surveillance to battle against highly contagious viruses in order to mitigate and prevent future global health emergencies.

Keywords: SARS-CoV-2; nanoparticles; point-of-use; rapid detection of virus; COVID-19

*Corresponding Author

E-mail: ashish84yadav@gmail.com (Ashish Yadav)

To cite this article: Yadav A et.al., *Advanced Nanomaterial Based Solutions To Mitigate The Challenges Of COVID-19 Pandemic*, *Biotechnol. kiosk*, Vol 3, Issue 2, PP: 5-24 (2021); DOI: <https://doi.org/10.37756/bk.21.3.2.1>.

1. Introduction

Since the outbreak of highly infectious coronavirus disease-2019 (COVID-19), the pandemic has brought devastating and life-altering effects across the globe by infecting millions of people in numerous countries so far [1,2]. The COVID-19 pandemic is caused by severe acute respiratory syndrome virus (SARS-CoV-2). It has been monitored by sequencing based detection and surveillance, contact tracing and epidemiological studies. Four major structural proteins have been shown that are considered to bind the RNA genome [3].

The D614G variant of SARS-CoV-2 was reported in the early stages of the outbreak. This variant was reported to be highly transmissible and was estimated about 70% more transmissible than the previously circulating form of the virus. Genome sequencing has revealed detailed evolution of SARS-CoV-2 [4]. Recent reports have confirmed a number of new variants known as B.1.1.7, B.1.351, and P.1 that have been first identified in the U.K., South Africa and Brazil. These variants are believed to be spreading quickly across the globe [5]. However, it is important to note that each variant may have possible attributes of lower classes.

In addition to genome sequencing and analysis of different variants, it is critical to have effective diagnostic tools and practices in place. Effective diagnostics can enable the rapid implementation of control measures—including infected patient identification followed by isolation—to limit the spread of the virus. In addition, an early diagnosis can be leveraged for contact tracing, which can

then enable identification of people that have been in contact with the infected persons. Figure 1 describes a workflow for the existing diagnostic practices for COVID-19 [1].

During the initial stages of the pandemic several different methods were utilized to determine the symptoms and morphology of the virus. Imagery from computerized tomography (CT) revealed pneumonia-like symptoms and abnormal lungs in infected people. Additionally, negative stained transmission electron microscopy (TEM) revealed dimension of the virus to be with diameter of about 60-140 nm. This dimension consisted of an envelope with spike proteins and genetic material (Figure 2[i]).

For detailed diagnostics, including genome sequencing of SARS-CoV-2, a multiplex polymerase chain reaction (PCR) panel of known pathogens was used to analyze the samples from infected patients. Subsequently, next generation sequencing was performed, which helped identify the previously unknown pathogen as an RNA virus [2]. Researchers then developed PCR kits by employing the whole genome sequence, which was used to diagnose COVID-19 [6]. We note that PCR/RT-PCR-based methods are widely used and commonly known as gold standard to detect nucleic acid of SARS-CoV-2 [1].

While PCR/RT-PCR-based methods represent the most common diagnostic approaches for COVID-19, they have some limitations. These methods are typically restricted in a centralized clinical laboratory, which requires sophisticated equipment and

well-trained personnel. In addition, the high demand for testing has significantly outpaced the scarce supply of PCR reagent kits. Furthermore, the reliance on RT-PCR in detection of SARS-CoV-2 in a sample makes it difficult to identify infection in a recovered asymptomatic patient (who was infected with the disease before), thereby hindering enforcement of control measures. In regards to CT based imaging procedures, they are quite expensive and require technical

expertise to diagnose COVID-19. Consequently, new innovations based on nanomaterials are now at the forefront of research, aimed at not only the diagnostic and detection component to mitigate COVID-19, but also at developing new antiviral drugs and vaccines. The following sections describe some of the notable advances made in nanomaterials-enabled solutions for battling COVID-19 [1].




Figure 1: Schematic illustration of a typical workflow showing the various steps that are involved in the diagnosis of the infection [Source: ACS Nano (2020)].




Figure 2: [i] (Upper Panel) A typical transmission electron microscope (TEM) image is presented that shows SARS-CoV-2 morphology. This morphology reveals spherical viral particles contained in a cell (virus in blue color). (Lower Panel) A schematic illustration of viral structure comprising structural viral proteins [Source: ACS Nano (2020)]. [ii] Different nanomaterials that can be synthesized through nanochemistry for battling against COVID 19 [Source: Nanomaterials, (2020)].

2. The Promise of Nanomaterials in Different Application Areas in the Fight Against COVID-19

It is generally believed that the COVID-19 pandemic might persist beyond 2020, which could add to the already tremendous stress on our global healthcare system. As a result, researchers are focusing on new nanotechnology-based innovations that promise to significantly alleviate this stress [7–14]. Nanochemistry, the combination of chemistry and nanoscience, is an important branch of modern nanotechnology and covers the synthesis of nanoparticle (NP) building blocks to generate unique functionalities depending on size, structure, surface, shape and defect properties [15]. A

range of NPs including protein NPs can be synthesized through nanochemistry routes for dedicated applications to mitigate challenges of COVID-19 (Figure 2) [1, 16].

2.1. Nanomaterial based Diagnostics

To combat COVID-19, nanomaterials are being implemented in the development of advanced diagnostics (such as point-of-care ‘POC’ diagnostics), carriers for therapeutics, and vaccine development. There is currently a huge research push among nanotech researchers to develop rapid, POC diagnostics for early detection of COVID-19 [17,18]. Rapid testing technology is vital to controlling the virus spread as people infected with SARS-CoV-2 exhibit a range of common respiratory infection symptoms such

as fever, cough or breathing troubles [19]. It is very important to make available rapid POC diagnostic tools that are also inexpensive for the frontline healthcare professionals in emergencies, clinics and hospitals. This would allow rapid diagnosis and identification of the infected patients that could be leveraged to enable frontline workers to isolate and take care of patients. This would prevent further spread of the virus [20].

2.1.1 Amino-Modified Magnetic Nanoparticles for Highly Sensitive Detection of COVID-19

It is known that an efficient extraction of RNA from clinical or biological samples is critically important for an accurate and timely

molecular diagnosis of COVID-19. However, the challenge is that the process of extraction is lengthy and also complex and labor intensive that makes it not favorable for a rapid diagnosis [8]. Researchers have attempted to overcome this shortcoming by employing poly (amino ester) with carboxyl groups and (PC)-coated magnetic nanoparticles (pcMNPs). The approach based on pcMNPs-enabled viral RNA extraction method was demonstrated for highly sensitive detection of SARS-CoV-2 [21]. Researchers showed the advantage of the method that used a combination of lysis and binding steps into a single step synthesis process that allowed direct incorporation of pcMNPs-RNA complexes into subsequent RT-PCR reactions (Figure 3)[21].




Figure 3: Schematic illustration showing the pcMNP-based viral RNA extraction method [Source: bioRxiv (2020)].

Further, purification of viral RNA from multiple samples within a short time period was demonstrated. Researchers identified two different regions (ORF1ab and N gene) of viral RNA and achieved a strong linear correlation between 10 and 105 copies of SARS-CoV-2 pseudovirus particles [21]. The

extraction method which is based on nanoparticles could pave the way for the development of alternative approaches that enable much reduced processing time and also minimizing possibility of false negative results in RT-PCR based diagnosis [18, 22, 23].

2.1.2. Point-of-Care Approach for SARS-CoV-2 Specific Antibody Detection

In a study based on magnetic immunodetection, Pietschmann et al [24] demonstrated a new POC approach for specific antibody detection of SARS-CoV-2 in human serum. Researchers compared the method with standard ELISA based method. In their approach, they coated immunofiltration columns with a SARS-CoV-2 spike peptide for magnetic immunodetection. They showed that SARS-CoV-2 peptide reactive antibodies spiked at different concentrations into PBS and human serum

that were rinsed through immunofiltration columns [1,24].

Researchers demonstrated retention of specific antibodies within the IFC labelled with an isotype specific biotinylated antibody. The secondary antibodies were labelled by using streptavidin-functionalized magnetic nanoparticles. Frequency magnetic mixing detection technology was applied for the detection of enriched magnetic nanoparticles. This was achieved by using a portable magnetic read-out device. Subsequently, signals were measured that corresponded to the amount of SARS-CoV-2 specific antibodies in the sample (Figure 4) [24].




Figure 4. A proof-of-concept level MInD assay setup is shown that is constructed by using an IFC coated SARS-CoV-2 antigen [Source: Front. Microbiol. 2021].

The proof-of-concept level magnetic immunodetection device exhibited promise for fast and POC detections as the new approach showed significantly higher sensitivity and

broader detection range that was shown to be a much more rapid process compared to the conventional ELISA based method [24].

2.1.3 FET Biosensor for the Detection of COVID-19

A novel field effect transistor 'FET' based biosensor was reported by Seo et al. [26] for detecting SARS-CoV-2 in clinical samples. Graphene sheets were used to produce the gate of the transistor that was subsequently coated with an antibody to develop the sensor. The chosen antibody was specific against the SARS-CoV-2 spike protein. Researchers then carried out measurements with antigen as protein along with cultured virus, and also nasal swab specimens from COVID-19 patients for the biosensor

performance test. The detection performance of FET biosensor was demonstrated for the SARS-CoV2 spike protein at concentrations of 1 fg/mL in buffer solvents that were prepared in the laboratory. Researchers then showed detection of viral strains in culture medium that was accomplished with a limit of detection of around 2.42×10^2 copies/mL in clinical samples. This study showed the possibility of using FET biosensors to detect the virus at even very low concentration of samples without the need of pretreatment or labeling (Figure 5) [25].




Figure 5: Schematic depiction of operation procedure of FET biosensor for the detection of COVID-19. In the device design, graphene is employed as a sensing material. The conjugation of SARS-CoV-2 spike antibody onto the graphene sheet is done via 1-pyrenebutyric acid N-hydroxysuccinimide ester [Source: ACS Nano 2020].

Mahari et al. studied a biosensor for COVID-19 in another recent work. This biosensor employed three electrode-electrochemical systems using disposable screen-printed carbon electrodes [26]. The biosensor was named eCovSens and the limit of detection

was shown to be 120 fM in buffer solvents. While the detection was performed in nonclinical samples, the electrodes were shown to be stable for up to 4 weeks (Figure 6).

In addition to diagnostics, the other area of major interest for researchers is developing nanotech-enabled smart surveillance and monitoring technologies to prevent future pandemics. It is believed that the

combination of rapid diagnostics and mass surveillance/monitoring technologies can significantly help public health officials monitor virus transmission and spread.




Figure 6: (A) A schematic illustration of FTO electrode is shown. (B) The working principle of fabricated electrode is illustrated [Source: bioRxiv 2020].

2.2. Antiviral Therapeutics and Vaccines

Heavy emphasis is being placed on antiviral therapeutics and vaccine development because they are essential to overcome the challenges of COVID-19. Developing effective therapeutics, including antiviral drugs and targeted drug delivery, by employing bioactive nanoparticles is at the forefront of current research aimed at treating COVID-19 patients. Recent research results have suggested the possibility of leveraging

novel therapeutics to block virus replication. More specifically, the focus is on to gain a better understanding of binding mechanism of the angiotensin converting enzyme receptor 2 (ACE2). It is believed that such a knowledge could lead to the discoveries of novel designs of therapeutics.

Vaccine development is currently the highest priority to combat COVID-19. The role of a vaccine is to boost the immune system against pathogens. The immune

system that gets a strong boost is considered instrumental in preventing disease. Researchers have considered a number of NPs including Ag and Au NPs, and also biomaterial-coated NPs for vaccines and other applications (Figure 7). The vaccines of choice in this current situation are novel protein subunit and nucleic acid vaccines derived from small components of SARS-CoV-2. Novel vaccines such as DNA and RNA present minimal risk of infection but might be incapable of reaching the antigen-presenting cells. To be effective, such vaccines would require efficient delivery systems or prime boosting with other immunogenic agents. Therefore, relatively low immune responses and insufficient expression of the immunogenic proteins by

these vaccines are the main factors that limit their use [27,28]. Subunit protein-based vaccines, derived from small components of pathogens, are becoming more popular due to the minimal side effects [29]. Human clinical trials and subsequent commercialization of RNA vaccines have offered huge promise in combating COVID-19 pandemic. However, such vaccines might require adjuvant and prime boosting in order to potentiate their immunogenicity. Thus, development of novel vaccines and efficient vaccine delivery systems with capacity to deliver the vaccine molecules to target sites and also acting as adjuvants to potentiate immunogenicity should take place simultaneously [30].




Figure 7: Schematic illustration of different NPs that are being considered in vaccines and other applications [Source: Future Medicine (2020)].

2.2.1. Self-Assembled Protein Nanoparticles for COVID-19 Vaccine

Researchers have found nanoparticles to be highly promising in developing safe vaccines against COVID-19 [17,31,32]. To this end, researchers have shown self-assembled nanoparticle technology for COVID-19 vaccine development. In this approach, a self-assembling nanoparticles-based technology (NSP10) with special surface properties has been proposed. This technology platform offers a versatile and rapid design and display of viral receptor stems than can work for virtually any virus. The NSP10-based technology can produce extremely high titers that have been shown in rabbits against a herpes viral protein called glycoprotein D. It has been shown that high titers can be advantageous to enhance protective immunity. This can be leveraged to reduce the quantity of vaccine per dose for use, which gives added advantages in safety and production scale of vaccine [15]. Researchers envisioned a number of advantages of NSP10-based vaccines. They hope that as the vaccine transitions for applications in humans, a single gram of plasmid DNA could potentially immunize over 2,000 people. This could bring a disruptive vaccine technology for COVID-19 [15].

2.3. Targeted Delivery of Drugs by Multidrug Nanoparticles to Combat Inflammation in COVID-19 Patients

Recent studies have shown that virally induced hyper inflammation might cause higher mortality in confirmed COVID-19

cases. The research evidence and findings have suggested that positive feedback loops between pro-inflammatory signaling and oxidative stress result in uncontrolled pro-inflammatory states [33]. It is considered a significant medical challenge to counter this activity in a targeted manner to control the inflammation in COVID-19 cases. To overcome this challenge, nanomaterials are being implemented to control the pro-inflammatory states. Especially, in a recent research, multidrug nanoparticles were shown to be effective in combatting inflammation in COVID-19 patients by leveraging drugs that are precisely delivered to the targets. These nanoparticles were synthesized by using conjugating squalene (a natural lipid) with adenosine, which is an endogenous immunomodulatory. The nanoparticles were then encapsulated using α -tocopherol, as antioxidant. Using this methodology, they demonstrated the applications of biocompatible, multidrug nanoparticles with high drug loading capacity. The multidrug nanoparticles were then used for targeted delivery of the therapeutic agents at sites of acute inflammation, which resulted in increased survival in treated animals in models of endotoxemia [34]. This study shows that selectively delivered adenosine and antioxidants taken in combination could pave the way for the development of a novel therapeutic approach that could be employed for effective treatment of acute paradoxal inflammation. Figure 8 shows preparation and characterization of squalene-Ad (SQAd)/VitE NPs.




Figure 8: (A) Schematic depiction of the preparation steps of SQAd bioconjugation and VitE encapsulation that is used to synthesize SQAd/VitE NPs. (B) The VitE encapsulation efficiency in SQAd/VitE NPs can be measured by liquid chromatography. (C) Hydrodynamic size measurement is shown for SQAd/VitE NPs. (D) Characterization for surface ζ -potential of SQAd/VitE and SQAd NPs is shown. (E) cryo-TEM images are shown for SQAd/VitE NPs. (F) Stability analysis of SQAd/VitE NPs in 50% fetal bovine serum and (G) adenosine from SQAd/VitE NPs is released in 50% FBS [**Source:** Science Advances (2020)].

It has been found that infections from COVID-19 could potentially aggravate a medical condition known as rhino-orbito-cerebral mucormycosis (ROCM), which is considered a progressive disease. Nanomaterials-assisted early diagnostic tools, especially POC diagnostics for COVID-19 are considered very promising for early detection and intervention in ROCM [36-38]. Killing bacteria/viruses that are present on a surface

is another research area where nanotech-enabled solutions are sought to battle against COVID-19. Superhydrophobic coating showed very good hemocompatibility with low fibrinogen adsorption and platelet activation [38,39]. These coatings were very successful in killing bacteria on the surface of clinical devices [40]. A superhydrophobic coating is a thin surface layer that repels water [41,42].

The study shows the utility of antiviral and antimicrobial active graphene-based coating on different surfaces to kill a number of viruses and bacteria. One area of application could be graphene coated surgical masks to mitigate the lethality of the transmission of COVID-19 [43,44].

2.5 Bioactive nanocoated surfaces

Airborne transmission from aerosols may be largely responsible for the spread of the virus. However, transmission from contaminated surfaces has also been implicated as one of the main routes through which the virus is spread from person to person. Studies have reported that SARS CoV-2 remains stable and viable on the surfaces for days after surface contamination; thus, providing a probable route for infecting healthy persons. Effective antiviral coatings can significantly inactivate the virus particles when they land on coated surfaces, thereby lowering the transmission rate [29]. Therefore, one of the most promising way to thwart contamination or to decontaminate surfaces, is the use of nanocoated bioactive surfaces with antimicrobial activity. Indeed, several studies have reported designing of self-decontamination surfaces using inorganic and organic nanoparticle-based composites such as silver, copper, zinc, gold, chitosan and graphene nanoparticles to coat surfaces. Copper nanoparticle-graphene composite based surface coating [45], silver, copper oxide and zinc oxide nanoparticle coatings [46], silver nanoparticle-chitosan based composites coating [47] effectively inactivated viruses in ex vivo experiments.

2.6. Antiviral nanocoated bioactive masks

COVID-19 is known to spread through human to human transmission, largely via respiratory droplets generated while sneezing, breathing, talking or coughing. (Lippi, Henry, Bovo, Sachis-Gomar, 2020). Simple personal protective equipment such as face masks have been reported to slow down the rate of COVID-19 transmission [47]). The use of cheap reusable double-cloth face masks by all individuals above 6 years is advocated for. However, the use of cloth masks is limited by irritability, the urge to adjust the mask frequently and low bacteria filtration capacity compared to medical masks. This promotes building of pathogens on the mask and eventually leakage of pathogens hence limiting their protective effectiveness. With advance in nanotechnology, the performance of cloth masks can be enhanced through functionalization with nanoparticles. The typical double cloth face masks by can be improved by filling their matrix with nanoparticles. Nanoparticles with proven antiviral activity such as silver, copper and titanium can be used to fabricate nanocoated bioactive masks using the pad dry cure method [48]. However, the performance and durability of the nanocoated masks can be improved by impregnating cotton cellulose nanofibers with a mixture of inorganic nanoparticles in a binder solution such as citric. The resultant fabric possesses superior antimicrobial activity and retains antimicrobial efficacy after numerous washings [49].

2.7 Nanobodies

Nanobodies are naturally occurring variants of antibodies expressed by camelids and made up of only the functional heavy-chains

(Figure 9). Lack of the light chains and the first conservative domains led the camelids' antibodies to attain a nanoscale size hence the term nanobodies [50]. Due to their distinguished properties such as natural origin, water solubility, nanoscale size, nonimmunogenic, and potent antigen-binding affinity, nanobodies have enticed great consideration for use as therapeutics and have entered clinical trials [51]. Zhao et al. generated MERS-CoV nanobodies by vaccination of llama with recombinant MERS-CoV receptor Bind domain (RBD) [52]. The resultant MERS-CoV RBD mRNA was reverse transcribed to cDNA. The cDNA was expressed in yeast cells using *Pichia pastoris* secretory expression vector to produce

MERS-CoV-RBD-specific nanobodies. Anti-MERS-CoV RBD nanobodies substantially blocked the docking of RBD to the cell-surface hDPP4 receptor, and displayed broad spectrum activity by neutralizing different MERS-CoV strains. Further, pre-exposure and post-exposure treatment with anti-MERS-CoV RBD nanobodies rescued 100% mice infected with lethal dose of MERS-CoV. Likewise, nanobodies targeting SARS-CoV-2 RBD which demonstrated high binding affinity for all the three SARS-CoV-2 RBDs spike trimer showing their potential of thwarting infection of the host by blocking host ACE-SARS-CoV-2 RBD interaction [53].




Figure 9: (Left) Standard human antibody with heavy and light chains joined by disulfide bridges. (Right) Camelid Single domain nanosized antibody (nanobody).

3. Conclusion and Future Perspective

We have presented an overview of nanotechnology-based solutions to strengthen the areas of diagnostics, protection and therapies in combatting COVID-19 pandemic. Nanotech-enabled solutions seem to be very promising to

address some of the most critical challenges in fighting against COVID-19 pandemic. It is anticipated that with more R&D, it would offer innovative processes, nanomaterials and techniques that can be leveraged to highly sensitive, reliable and rapid diagnostics

including point-of-care (POC) diagnostics to battle against highly contagious viral diseases such as COVID-19 and any other future outbreaks. In the very important areas of diagnosis, therapeutics and vaccine development, nanomaterials are being implemented to provide the much-needed solutions to a complex set of challenges of neutralizing the novel coronavirus. This field of research is currently evolving and we anticipate more breakthroughs happening in the very near future, considering the rapid pace of research and developments.

The common consensus is that an effective and multi-disciplinary as well as multi-national collaboration is needed between various governmental stakeholders to mitigate quickly any global health emergencies in future. One suggestion that has been gaining ground among researchers and policy makers is developing and establishing robust and cooperative networks between regulatory and government agencies together with research centers, various universities, commercial companies, and the medical and healthcare communities across the globe to fight against pandemics to benefit and protect our societies.

Acknowledgement

Authors from Makerere University, Kampala, Uganda gratefully acknowledge research funding from the Africa Center of Excellence in Materials, Product Development and Nano-Technology (MAPRONANO-ACE). Dr. Ashish Yadav gratefully acknowledges financial support from the Taishan scholar scheme of Shandong province, People's Republic of China (TS20190401).

References

1. Udugama, B.; Kadhiresan, P.; Kozlowski, H.N.; Malekjahani, A.; Osborne, M.; Li, V.Y.C.; Chen, H.; Mubareka, S.; Gubbay, J.B.; Chan, W.C.W. Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* 2020, 14, 3822–3835, doi: <https://doi.org/10.1021/acsnano.0c02624>.
2. Li Q.; Guan X.; Wu P.; Wang X.; Zhou L.; Tong Y.; Ren R.; Leung Kathy S.M. et. al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *NEJM* 2020, 382, 1199-1207, doi: <https://doi.org/10.1056/NEJMoa2001316>.
3. Kang, S.; Peng W.; Zhu Y.; Lu S.; Zhou M.; Lin W.; Wu W.; Huang S.; Jiang L.; Luo X.; Deng M.; Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment, *International Journal of Antimicrobial Agents*, 2020, 55 (5), 105950, doi: <https://doi.org/10.1016/j.ijantimicag>
4. Li, T., Liu, D., Yang, Y. *et al.* Phylogenetic supertree reveals detailed evolution of SARS-CoV-2. *Sci Rep* 2020, 10, 22366, doi: <https://doi.org/10.1038/s41598-020-79484-8>.
5. Hodcroft, E.B.; Zuber, M.; Nadeau, S.; Crawford, K.H.D.; Bloom, J.D.; Veerler, D.; Vaughan, T.G.; Comas, I.; Candelas, F.G.; Stadler, T.; et al. Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. *medRxiv* 2021, doi: <https://doi.org/10.1101/2020.10.25.20219063>.
6. Ma, X.; Ph, D.; Wang, D.; Ph, D.; Xu, W.; Wu, G.; Gao, G.F.; Phil, D.; Tan, W.; Ph, D.

- A Novel Coronavirus from Patients with Pneumonia in China, 2019. 2020, 1–7, doi: <https://doi.org/10.1056/NEJMoa2001017>.
7. Chauhan, G.; Madou, M.J.; Kalra, S.; Chopra, V.; Ghosh, D.; Martinez-Chapa, S.O. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. *ACS Nano* 2020, 14, 7760–7782, doi: <https://doi.org/10.1021/acsnano.0c04006>.
 8. Sportelli, M.C.; Izzi, M.; Kukushkina, E.A.; Hossain, S.I.; Picca, R.A.; Ditaranto, N.; Cio, N. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? 2020, 21;10(4):802, doi: <https://doi.org/10.3390/nano10040802>.
 9. Nasrollahzadeh, M.; Sajjadi, M.; Soufi, G.J.; Irvani, S.; Varma, R.S. Nanomaterials and nanotechnology-associated innovations against viral infections with a focus on coronaviruses. *Nanomaterials* 2020, 10, doi: <https://doi.org/10.3390/nano10061072>.
 10. Weiss, C.; Carriere, M.; Fusco, L.; Fusco, L.; Capua, I.; Regla-Nava, J.A.; Pasquali, M.; Pasquali, M.; Pasquali, M.; Scott, J.A.; et al. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. *ACS Nano* 2020, 14, 6383–6406, doi: <https://doi.org/10.1021/acsnano.0c03697>.
 11. Talebian, S.; Wallace, G.G.; Schroeder, A.; Stellacci, F.; Conde, J. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. *Nat. Nanotechnol.* 2020, 15, 618–621, doi: <https://doi.org/10.1038/s41565-020-0751-0>.
 12. Vazquez-Munoz, R.; Lopez-Ribot, J.L. Nanotechnology as an Alternative to Reduce the Spread of COVID-19. *Challenges* 2020, 11, 15, doi: <https://doi.org/10.3390/challe11020015>.
 13. Yang D. Application of Nanotechnology in the COVID-19 Pandemic. *Int J Nanomedicine.* 2021, 16, 623-649, doi: <https://doi.org/10.2147/IJN.S296383>.
 14. Arora, S.; Yadav, V.; Kumar, P.; Gupta, R.; Kumar, D. Polymer based antimicrobial coatings as potential biomaterial: A review. *Int. J. Pharm. Sci. Rev. Res.* 2013, 23, 279–290.
 15. Carter, D.C.; Wright, B.; Jerome, W.G.; Rose, J.P.; Wilson, E. A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production. *Journal of Nanomaterials*, 2020, Article ID 4297937, doi: <https://doi.org/10.1155/2020/4297937>.
 16. Sivasankarapillai, V.S.; Pillai, A.M.; Rahdar, A.; Sobha, A.P.; Das, S.S.; Mitropoulos, A.C.; Mokarrar, M.H.; Kyzas, G.Z. On facing the SARS-cov-2 (COVID-19) with combination of nanomaterials and medicine: Possible strategies and first challenges. *Nanomaterials* 2020, 10, 1–23, doi: <https://doi.org/10.3390/nano10050852>.
 17. Medhi, R.; Srinoi, P.; Ngo, N.; Tran, H.V.; Lee, T.R. Nanoparticle-Based Strategies to Combat COVID-19. *ACS Appl. Nano Mater.* 2020, 3, 8557–8580, doi: <https://doi.org/10.1021/acsanm.0c01978>.
 18. Qin, Z.; Peng, R.; Baravik, I.K.; Liu, X. Fighting COVID-19: Integrated Micro- and Nanosystems for Viral Infection Diagnostics. *Matter* 2020, 3, 628–651, doi: <https://doi.org/10.1016/j.matt.2020.06.015>.
 19. Kudapa, V.K.; Nayak, N.P.; Gupta, R.; Studies, E.; Studies, E. Materials for diagnosis, prevention and control of COVID-19, 2020, 2, 4-17, doi: <https://doi.org/10.37756/bk.20.2.9.1>.

20. Nano Research for COVID-19. 2019, doi: <https://doi.org/10.1021/acsnano.0c02540>.
21. Zhao, Z.; Cui, H.; Song, W.; Ru, X.; Zhou, W.; Yu, X. A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. *bioRxiv*, 2020, 518055, doi: <https://doi.org/10.1101/2020.02.22.961268>
22. Bhasker Dharavath, Yadav Neelima, Desai Sanket, Sunder Roma, et. al., A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2, *Heliyon*, 6 (7), e04405, 2020, <https://doi.org/10.1016/j.heliyon.2020.e04405>.
23. Rabiee, N.; Bagherzadeh, M.; Ghasemi, A.; Zare, H.; Ahmadi, S.; Fatahi, Y.; Dinarvand, R.; Rabiee, M.; Ramakrishna, S.; Shokouhimehr, M.; et al. Point-of-use rapid detection of sars-cov-2: Nanotechnology-enabled solutions for the covid-19 pandemic. *Int. J. Mol. Sci.* 2020, 21, 1–23, doi: <https://doi.org/10.3390/ijms21145126>.
24. Pietschmann, J.; Voepel, N.; Voß, L.; Rasche, S.; Schubert, M.; Kleines, M.; Krause, H.J.; Shaw, T.M.; Spiegel, H.; Schroeper, F. Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay. *Front. Microbiol.* 2021, 12, 1–11, doi: <https://doi.org/10.3389/fmicb.2021.643275>.
25. Seo, G.; Lee, G.; Kim, M.J.; Baek, S.H.; Choi, M.; Ku, K.B.; Lee, C.S.; Jun, S.; Park, D.; Kim, H.G.; et al. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano* 2020, 14, 5135–5142, doi: <https://doi.org/10.1021/acsnano.0c02823>.
26. Mahari, S.; Roberts, A.; Shahdeo, D.; Gandhi, S. Ecovsens-ultrasensitive novel in-house built printed circuit board based electrochemical device for rapid detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2. *bioRxiv* 2020, doi: <https://doi.org/10.1101/2020.04.24.059204>
27. Zhao, K.; Han, J.; Zhang, Y.; Wei, L.; Yu, S.; Wang, X.; Jin, Z.; Wang, Y. Enhancing Mucosal Immune Response of Newcastle Disease Virus DNA Vaccine Using N-2-Hydroxypropyl Trimethylammonium Chloride Chitosan and N,O-Carboxymethyl Chitosan Nanoparticles as Delivery Carrier. *Mol. Pharm.* 2018, 15, 226–237, doi: <https://doi.org/10.1021/acs.molpharmaceut.7b00826>.
28. Jeremiah, S.S.; Miyakawa, K.; Morita, T.; Yamaoka, Y.; Ryo, A. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. *Biochem. Biophys. Res. Commun.* 2020, 533, 195–200, doi: <https://doi.org/10.1016/j.bbrc.2020.09.01>
29. Bastola, P.; Oien, D.B.; Cooley, M.; Chien, J. Emerging Cancer Therapeutic Targets in Protein Homeostasis. *AAPS J.* 2018, 20, doi: <https://doi.org/10.1208/s12248-018-0254-1>.
30. Borah P, Deb PK, Al-Shar'i NA, et al. Perspectives on RNA Vaccine Candidates for COVID-19. *Front Mol Biosci.* 2021, 8, 635245, doi: <https://doi.org/10.3389/fmolb.2021.635245>
31. Itani, R.; Tobaiqy, M.; Faraj, A. AI Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. *Theranostics.* 2020, 10, 5932–

- 5942, doi: <https://doi.org/10.7150/thno.46691>.
32. Shin, M.D.; Shukla, S.; Chung, Y.H.; Beiss, V.; Chan, S.K.; Ortega-Rivera, O.A.; Wirth, D.M.; Chen, A.; Sack, M.; Pokorski, J.K.; et al. COVID-19 vaccine development and a potential nanomaterial path forward. *Nat. Nanotechnol.* 2020, 15, 646–655, doi: <https://doi.org/10.1038/s41565-020-0737-y>.
33. Campos, E.V.R.; Pereira, A.E.S.; De Oliveira, J.L.; Carvalho, L.B.; Guilger-Casagrande, M.; De Lima, R.; Fraceto, L.F. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. *J. Nanobiotechnology.* 2020, 18, 1–23, doi: <https://doi.org/10.1186/s12951-020-00685-4>.
34. Dormont, F.; Brusini, R.; Cailleau, C.; Reynaud, F.; Reynaud, F.; Peramo, A.; Gendron, A.; Mougin, J.; Gaudin, F.; Gaudin, F.; et al. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. *Sci. Adv.* 2020, 6, 1–12, doi: <https://doi.org/10.1126/sciadv.aaz5466>.
35. Honavar, Santosh G, Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19. *Indian Journal of Ophthalmology* 2021, 69(6), 1361-1365, doi: https://doi.org/10.4103/ijo.IJO_1165_21.
36. Skiada A.; Lass-Floerl C.; Klimko N.; Ibrahim A.; Roilides E.; Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. *Medical Mycology* 2018, 56, S93–S101, doi: <https://doi.org/10.1093/mmy/myx101>.
37. Awal, S.S., Biswas, S.S. & Awal, S.K. Rhino-orbital mucormycosis in COVID-19 patients—a new threat?. *Egypt J Radiol Nucl Med* 2021, 52, 152, doi: <https://doi.org/10.1186/s43055-021-00535-9>.
38. Hooda, A.; Goyat, M.S.; Kumar, A.; Gupta, R. A facile approach to develop modified nano-silica embedded polystyrene based transparent superhydrophobic coating. *Mater. Lett.* 2018, 233, 340–343, doi: <https://doi.org/10.1016/j.matlet.2018.09.043>.
39. Hooda, A.; Goyat, M.S.; Gupta, R.; Prateek, M.; Agrawal, M.; Biswas, A. Synthesis of nano-textured polystyrene/ZnO coatings with excellent transparency and superhydrophobicity. *Mater. Chem. Phys.* 2017, 193, 447–452, doi: <https://doi.org/10.1016/j.matchemphys.2017.03.011>.
40. Liu, S.; Zheng, J.; Hao, L.; Yegin, Y.; Bae, M.; Ulugun, B.; Taylor, T.M.; Scholar, E.A.; Cisneros-Zevallos, L.; Oh, J.K.; et al. Dual-Functional, Superhydrophobic Coatings with Bacterial Anticontact and Antimicrobial Characteristics. *ACS Appl. Mater. Interfaces* 2020, 12, 21311–21321, doi: <https://doi.org/10.1021/acsami.9b18928>.
41. Sharma, V.; Goyat, M.S.; Hooda, A.; Pandey, J.K.; Kumar, A.; Gupta, R.; Upadhyay, A.K.; Prakash, R.; Kirabira, J.B.; Mandal, P.; et al. Recent progress in nano-oxides and CNTs based corrosion resistant superhydrophobic coatings: A critical review. *Prog. Org. Coatings* 2020, 140, 105512, doi: <https://doi.org/10.1016/j.porgcoat.2019.10.5512>.

42. Hooda, A.; Goyat, M.S.; Kumar, J.; Kumar, A.; Gupta, R. Progress in Organic Coatings A review on fundamentals , constraints and fabrication techniques of superhydrophobic coatings. Prog. Org. Coatings 2020, 142, 105557, doi: <https://doi.org/10.1016/j.porgcoat.2020.105557>.
43. Kumar Raghav, P.; Mohanty, S. Are graphene and graphene-derived products capable of preventing COVID-19 infection? Med. Hypotheses 2020, 144, 110031, doi: <https://doi.org/10.1016/j.mehy.2020.110031>.
44. Palmieri, V.; Papi, M. Nano Today Can graphene take part in the fight against COVID-19? Nano Today 2020, 33, 100883, doi: <https://doi.org/10.1016/j.nantod.2020.100883>.
45. Das Jana, I.; Kumbhakar, P.; Banerjee, S.; Gowda, C.C.; Kedia, N.; Kuila, S.K.; Banerjee, S.; Das, N.C.; Das, A.K.; Manna, I.; et al. Copper Nanoparticle-Graphene Composite-Based Transparent Surface Coating with Antiviral Activity against Influenza Virus. ACS Appl. Nano Mater. 2021, 4, 352–362, doi: <https://doi.org/10.1021/acsanm.0c02713>.
46. Merkl, P.; Long, S.; McInerney, G.M.; Sotiriou, G.A. Antiviral activity of silver, copper oxide and zinc oxide nanoparticle coatings against sars-cov-2. Nanomaterials 2021, 11, doi: <https://doi.org/10.3390/nano11051312>.
47. Mori, Y.; Ono, T.; Miyahira, Y.; Nguyen, V.Q.; Matsui, T.; Ishihara, M. Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus. Nanoscale Res. Lett. 2013, 8, 93, doi: <https://doi.org/10.1186/1556-276x-8-93>.
48. Hebeish, A.; El-Naggar, M.E.; Fouda, M.M.G.; Ramadan, M.A.; Al-Deyab, S.S.; El-Rafie, M.H. Highly effective antibacterial textiles containing green synthesized silver nanoparticles. Carbohydr. Polym. 2011, 86, 936–940, doi: <https://doi.org/10.1016/j.carbpol.2011.05.048>.
49. Saleem, H.; Zaidi, S.J. Sustainable use of nanomaterials in textiles and their environmental impact. Materials (Basel). 2020, 13, 1–28, doi: <https://doi.org/10.3390/ma13225134>.
50. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hammers, C.; Songa, E.B.; Bendahman, N.; Hammers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363, 446–448, doi: <https://doi.org/10.1038/363446a0>.
51. Keyaerts, M.; Xavier, C.; Heemskerk, J.; Devoogdt, N.; Everaert, H.; Ackaert, C.; Vanhoeij, M.; Duhoux, F.P.; Gevaert, T.; Simon, P.; et al. Phase i study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J. Nucl. Med. 2016, 57, 27–33, doi: <https://doi.org/10.2967/jnumed.115.162024>.
52. Zhao, G.; He, L.; Sun, S.; Qiu, H.; Tai, W.; Chen, J.; Li, J.; Chen, Y.; Guo, Y.; Wang, Y.; et al. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J. Virol. 2018, 92, doi: <https://doi.org/10.1128/jvi.00837-18>.

53. Huo, J.; Le Bas, A.; Ruza, R.R.; Duyvesteyn, H.M.E.; Mikolajek, H.; Malinauskas, T.; Tan, T.K.; Rijal, P.; Dumoux, M.; Ward, P.N.; et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD

and block interaction with ACE2. *Nat. Struct. Mol. Biol.* 2020, 27, 846–854, doi: <https://doi.org/10.1038/s41594-020-0469-6>.



Rights and Permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Creative Commons This is an open access article distributed under the terms of the [Creative Commons CC BY](https://creativecommons.org/licenses/by/4.0/) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You are not required to obtain permission to reuse this article. To request permission for a type of use not listed, please contact Biotechnology Kiosk.



Biotechnology Advances around the World

Editor's Picks

Every issue of Biotechnology Kiosk presents select latest research news picked by the editors-in-chief on significant research breakthroughs in different areas of biotechnology around the world. The aim is to promote further R&D in all of these cutting-edge areas of biotechnology. The editors have compiled and included the following innovations and breakthroughs to highlight the latest biotechnology advances.



Dr. Megha Agrawal
Co Editor-in-Chief



Dr. Shyamasri Biswas
Co Editor-in-Chief

Multiple Sclerosis

Stem cell transplant in multiple sclerosis

It is known that most people with multiple sclerosis (MS) are first diagnosed with relapsing-remitting MS, which is marked by symptom flare-ups followed by periods of remission. However, studies have shown that relapsing-remitting MS in many people can eventually transition to secondary progressive MS, which is not associated with wide swings in symptoms but instead a slow, steady worsening of the disease is observed.

The available conventional treatment pathways have prevented people with MS from experiencing more attacks and worsening symptoms. However, these treatments cannot prevent people with MS in the long term. Previous research showed that more than half of the people with MS taking medication for their disease experienced worsening condition over a 10-year period.

A new study by a team of Italian researchers showed that intense immunosuppression followed by a hematopoietic stem cell transplant could potentially prevent disability associated with MS from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The study found improvement in some people with their disability over 10 years after treatment. Their research was published in the January 20, 2021, online issue of *Neurology*[®], the medical journal of the American Academy of Neurology (Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. *Neurology*, 2021 DOI: 10.1212/WNL.0000000000011461).

This study also showed that more than half of the people with the secondary progressive form of MS experienced no worsening of their symptoms 10 years after a stem cell transplant.

These results are shown to be exciting due to the fact that they show hematopoietic stem cell transplants may prevent someone's MS disabilities from getting worse over the longer term. Researchers studied over a time period of five years and found that a majority of the people experienced no worsening of their MS disability. Further, at the 10-year mark, a significant percentage of them still had not experienced a worsening of disability.

Researchers looked at just the people with the most common form of MS and found 86% of them experienced no worsening of their disability five years after their transplant. Ten years later, 71% of them still experienced no worsening of their disability.

Also, researchers studied people with progressive MS benefited from stem cell transplants and found that 71% of the people with this type of MS experienced no worsening of their disability five years after their transplants. Ten years later, 57% experienced no worsening of their disability.

This study paves the way for further development of intense immunosuppression followed by hematopoietic stem cell transplants that could be considered as a treatment for people with MS, especially those who don't respond to conventional therapy.

Gut Microbe

Gut microbe is linked to the development of breast cancer

A recent study showed that microbe found in the colon and commonly associated with the development of colitis and colon cancer may play a role in the development of some breast cancers. A team of researchers in the United States at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy demonstrated that breast tissue cells exposed to this toxin can potentially retain a long-term memory that can increase the risk for disease. In this study, researchers discovered that introduction of enterotoxigenic *Bacteroides fragilis* (ETBF) to the guts or breast ducts of mice always induced growth and metastatic progression of tumor cells. They found that breast cells exposed to the toxin for 72 hours retained a memory of the toxin and were able to start cancer development and form metastatic lesions in different mouse models. They also found the Notch1 and beta-catenin cell signaling pathways to be involved in promoting EBFT's role in breast tissue. A description of their work was published in the January 6 issue of the journal *Cancer Discovery* (A pro-carcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates Notch and β catenin axes. *Cancer Discovery*, 2021; CD-20-0537 DOI: 10.1158/2159-8290.CD-20-0537).

While it is known that microbes are present in body sites such as the gastrointestinal tract, nasal passages and skin, breast tissue has always been considered sterile. However, this study that showed the involvement of ETBF in breast cancer development proved that such considerations may not be always valid. Further, this study paves the way for additional research to clarify how ETBF moves throughout the body. Especially, the questions related to whether ETBF can be a sole driver to directly trigger the transformation of breast cells in humans, and/or if other microbiota also have cancer-causing activity for breast tissue need to be addressed.

A large number of breast cancers arise in women harboring none of the established multiple risk factors for breast cancer that include age, genetic changes, radiation therapy and family history. This study suggested another risk factor involving microbiome. If the microbiome gets perturbed, or if it harbors toxigenic microbes with oncogenic function, that could lead to an additional risk factor for breast cancer.

Compiled and Edited by Dr. Megha Agrawal & Dr. Shyamasri Biswas.



VACUUM TECHNOLOGY & COATING

Claim Your Free Digital Subscription to VT&C

Vacuum Technology & Coating Magazine has been the only publication dedicated exclusively to the Vacuum Processing and Thin Film Deposition industries since it was founded in 2000.

Each monthly issue includes columns focused on Thin Film Deposition, Vacuum Processing, Characterization of Thin Films, Nanotechnology and Biotechnology, often with guest editorial by scientists and manufacturers in the industry.

Monthly Product Showcases introduce the latest products with a wide range of topics including: Deposition and Coating Equipment, Furnaces, Ovens, Chillers and Cryosystems, Vacuum Hardware, Gas Handling and Gas Analytical Systems, Measurement and Metrology, Materials, and Vacuum Pumps, and many more.

Subscribe to *Vacuum Technology & Coating* Magazine Today!



Print or Digital

<http://www.vtcmag.com/subscribe.html>



vacuum TECHNOLOGY
& coating

www.vtcmag.com



For all production related questions or sending your ads, please e-mail or call our production department: E-mail: sales@biotechkiosk.com; Phone: 386-518-9411.

THANK YOU!

